Orthocell Limited (ASX: OCC)
Health Care · Biotechnology · AU
AU$0.69
-9.21% today · -52.4% 1Y
Orthocell Limited (ASX: OCC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $131.16M and employs 37 people.
Over the last twelve months the share price has lost 52.4%, trading between 0.67 and 1.59.
Tweenvest scores Orthocell Limited across four factors: quality 39/100, value 62/100, growth 100/100. Its strongest factor is growth.
OCC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $131.16M
- Revenue (TTM)
- $7.89M
- P/E
- —
- EPS
- -0.05
- Dividend yield
- —
- Beta (5Y)
- -0.03
- 52-week high
- AU$1.59
- 52-week low
- AU$0.67
- Avg volume (3M)
- —
- Shares outstanding
- 272.39M
- Employees
- 37
- Next earnings
- —
About Orthocell Limited
Headquartered in Murdoch, Australia, Orthocell Limited, established in 2006, operates as a regenerative medicine company focused on creating and bringing to market advanced cell therapies and biological medical devices. These innovations are designed to facilitate the healing of a range of bone and soft tissue injuries. The company's product lineup includes CelGro, a naturally derived collagen medical device engineered to augment surgical repair across various indications, including bone, peripheral nerves, tendons, and cartilage. Another key offering is Ortho-ATI, a specialized cell therapy developed for the treatment of chronic tendon injuries. Furthermore, Orthocell provides Ortho-ACI, an autologous chondrocyte implantation technique aimed at repairing articular cartilage defects in the knee and ankle. Its portfolio also features Striate+, a biodegradable collagen membrane employed for guided bone and tissue regeneration in dental applications, and Remplir, a collagen scaffold utilized for the restoration of peripheral nerves.
- ISIN
- AU000000OCC6
- Founded
- 2006
- Listed since
- Aug 12, 2014
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Innate Pharma S.A.ENXTPA: IPH | $134.19M | €1.28 | -1.54% |
| NIBEC Co., Ltd.KOSDAQ: A138610 | $132.33M | ₩15,650.00 | -2.07% |
| StemCyte International, Ltd.TWSE: 4178 | $132.32M | NT$19.60 | +8.89% |
| Saniona AB (publ)OM: SANION | $132.11M | Skr9.57 | -0.26% |
| Tenaya Therapeutics, Inc.NasdaqCM: TNYA | $130.12M | $0.57 | -2.55% |
| NKGen Biotech Korea Co., Ltd.KOSDAQ: A182400 | $128.86M | ₩— | — |
| Spruce Biosciences, Inc.NasdaqCM: SPRB | $126.60M | $42.87 | -2.68% |
| Bio Solution Co.,Ltd.KOSDAQ: A086820 | $126.49M | ₩6,590.00 | -1.64% |
Figures last refreshed Oct 11, 2026.